4-AndrostenediolCAS# 1156-92-9 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1156-92-9 | SDF | Download SDF |
PubChem ID | 136297 | Appearance | Powder |
Formula | C19H30O2 | M.Wt | 290.4 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol | ||
SMILES | CC12CCC3C(C1CCC2O)CCC4=CC(CCC34C)O | ||
Standard InChIKey | BTTWKVFKBPAFDK-LOVVWNRFSA-N | ||
Standard InChI | InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,13-17,20-21H,3-10H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
4-Androstenediol Dilution Calculator
4-Androstenediol Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.4435 mL | 17.2176 mL | 34.4353 mL | 68.8705 mL | 86.0882 mL |
5 mM | 0.6887 mL | 3.4435 mL | 6.8871 mL | 13.7741 mL | 17.2176 mL |
10 mM | 0.3444 mL | 1.7218 mL | 3.4435 mL | 6.8871 mL | 8.6088 mL |
50 mM | 0.0689 mL | 0.3444 mL | 0.6887 mL | 1.3774 mL | 1.7218 mL |
100 mM | 0.0344 mL | 0.1722 mL | 0.3444 mL | 0.6887 mL | 0.8609 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2'-Hydroxygenistein
Catalog No.:BCN6036
CAS No.:1156-78-1
- Marbofloxacin hydrochloride
Catalog No.:BCC4250
CAS No.:115551-26-3
- Marbofloxacin
Catalog No.:BCC2510
CAS No.:115550-35-1
- BI 224436
Catalog No.:BCC5531
CAS No.:1155419-89-8
- Fmoc-Cys(Trt)-Opfp
Catalog No.:BCC3480
CAS No.:115520-21-3
- (2-Amino-1-hydroxyethyl)phosphonic acid
Catalog No.:BCN1613
CAS No.:115511-00-7
- H-Lys(Z)-OH
Catalog No.:BCC2986
CAS No.:1155-64-2
- Z-Glu-OH
Catalog No.:BCC2781
CAS No.:1155-62-0
- 5,6,7,7a-Tetrahydrothieno[3,2-c]pyridine-2(4H)-one hydrochloride
Catalog No.:BCC8721
CAS No.:115473-15-9
- Glaucin B
Catalog No.:BCN6035
CAS No.:115458-73-6
- Sootepin D
Catalog No.:BCN6034
CAS No.:1154518-97-4
- Risedronate Sodium
Catalog No.:BCC2501
CAS No.:115436-72-1
- Cinnamyl coumarate
Catalog No.:BCN7739
CAS No.:115610-30-5
- Cinnamyl isoferulate
Catalog No.:BCN7718
CAS No.:115610-31-6
- Cinnamyl caffeate
Catalog No.:BCN7721
CAS No.:115610-32-7
- H-DL-Pro-NH2
Catalog No.:BCC3027
CAS No.:115630-49-4
- B2
Catalog No.:BCC7505
CAS No.:115687-05-3
- Daidzein dimethyl ether
Catalog No.:BCN6761
CAS No.:1157-39-7
- Adonifoline
Catalog No.:BCN2056
CAS No.:115712-88-4
- 6'-O-beta-D-Glucosylgentiopicroside
Catalog No.:BCN2814
CAS No.:115713-06-9
- 1-O-galloyl-6-O-cinnamoylglucose
Catalog No.:BCN8264
CAS No.:115746-69-5
- Galanolactone
Catalog No.:BCN6037
CAS No.:115753-79-2
- 15,16-Dihydro-15-methoxy-16-oxohardwickiic acid
Catalog No.:BCN1612
CAS No.:115783-35-2
- ent-Atisane-3beta,16alpha,17-triol
Catalog No.:BCN6626
CAS No.:115783-44-3
The potential of urinary androstdiene markers to identify 4-androstenediol (4-ADIOL) administration in athletes.[Pubmed:21177052]
Forensic Sci Int. 2011 May 20;208(1-3):129-38.
Doping control laboratories accredited by the World Anti-Doping Agency (WADA) require criteria that allow endogenous steroids to be distinguished from their synthetic analogues in urine. Methodology based on "looking outside the metabolic box" was used in this study to identify diagnostic urinary markers of 4-Androstenediol (4-ADIOL) administration. Androst-2,4-diene-17-one and androst-3,5-diene-17-one are proposed to be formed in urine from acid-catalyzed hydrolysis of 4-ADIOL sulfoconjugate, a major phase II metabolic product of 4-ADIOL. The presence of these markers in the routine gas chromatography-mass spectrometry (GC-MS) steroid screen was suitable to identify samples requiring confirmation by gas chromatography-combustion-isotope ratio mass spectrometry (GC-C-IRMS) - to measure the carbon isotope ratio (delta(13)C) of the androstdiene markers and confirm their likely synthetic origin based on depleted (13)C content.
Urinary metabolic profile of 19-norsteroids in humans: glucuronide and sulphate conjugates after oral administration of 19-nor-4-androstenediol.[Pubmed:18763272]
Rapid Commun Mass Spectrom. 2008 Oct;22(19):3035-42.
19-Nor-4-Androstenediol (NOL) is a prohormone of nandrolone (ND). Both substances are included in the WADA List of Prohibited Classes of Substances and their administration is determined by the presence of 19-norandrosterone (NA) with the urinary threshold concentration of 2 ng mL(-1). Routine analytical procedures allow the determination of NA excreted free and conjugated with glucuronic acid, but amounts of ND and NOL metabolites are also excreted in the sulphate fraction. The aim of this study is to determine the urinary metabolic profile after oral administration of a nutritional supplement containing NOL. Urine samples were collected up to 96 h following supplement administration and were extracted to obtain separately three metabolic fractions: free, glucuronide and sulphate. Extraction with tert-butyl methyl ether was performed after the hydrolysis steps and trimethylsilyl derivatives were analyzed by gas chromatography/mass spectrometry (GC/MS). After oral administration of NOL, the main metabolites detected were NA and noretiocholanolone (NE) in the glucuronide and sulphate fractions. The relative abundances of each metabolite in each fraction fluctuate with time; a few hours after administration the main metabolite was NA glucuronide whereas in the last sample (4 days after administration) the main metabolite was the NA sulphate and the second was the NE glucuronide. During the studied period almost half of the dose was excreted and the main metabolites were still found in urine after 96 h. Norepiandrosterone and norepietiocholanolone were also detected only in the sulphate fraction. Our results suggest that sulphate metabolites should be taken into consideration in order to increase the retrospectivity in the detection of 19-norsteroids after oral administration.
Gas chromatography-mass spectrometry method for the analysis of 19-nor-4-androstenediol and metabolites in human plasma: application to pharmacokinetic studies after oral administration of a prohormone supplement.[Pubmed:18423786]
Steroids. 2008 Aug;73(7):751-9.
19-Nor-4-Androstenediol is a prohormone of nandrolone. Both substances are included in the WADA list of prohibited classes of substances. The aim of this study is to determine the plasma levels of 19-nor-4-Androstenediol and its metabolites after oral administration of a nutritional supplement containing the drug. Two capsules of Norandrodiol Select 300 were orally administered to six healthy male volunteers. Plasma samples were collected up to 24h. Samples were extracted to obtain free and glucuronoconjugated metabolic fractions. Trimethylsilyl derivatives of both fractions were analyzed by gas chromatography coupled to mass spectrometry (GC-MS). The method was validated to determine linearity, extraction recovery, limit of detection and quantification, intra- and inter-day precision and accuracy. After administration of 19-nor-4-Androstenediol, the main metabolites detected were norandrosterone and noretiocholanolone, mainly in the glucuronide fraction. Nandrolone, norandrostenedione and 19-nor-4-Androstenediol were also detected at lower concentrations.
Tissue selectivity of the anabolic steroid, 19-nor-4-androstenediol-3beta,17beta-diol in male Sprague Dawley rats: selective stimulation of muscle mass and bone mineral density relative to prostate mass.[Pubmed:18096666]
Endocrinology. 2008 Apr;149(4):1987-93.
Stimulation of prostate growth is a major concern with testosterone therapy in older hypogonadal men. As a result, nonsteroidal selective androgen receptor modulators with anabolic activity but less prostate stimulation are being developed. Anabolic steroids might exhibit similar tissue selectivity. We hypothesized the anabolic steroid 19-nor-4-Androstenediol-3beta,17beta-diol (3beta,19-NA) would increase muscle, lean body mass (LBM), and bone mineral density (BMD) with little stimulation of prostate growth. Male Sprague Dawley rats were implanted with SILASTIC brand (Dow Corning, Midland, MI) capsules containing 3beta,19-NA (4, 8, or 16 cm), dihydrotestosterone (DHT) (8 cm), 19-nortestosterone (16 cm), or four empty capsules after undergoing either a sham operation (intact) or orchidectomy (ORX). Serum gonadotropins, measured after 4, 8, or 24 wk of treatment, were significantly lower in 3beta,19-NA-treated vs. untreated, intact, and ORX rats (P < 0.05), and testosterone was lowered by 3beta,19-NA-treatment of intact animals. LBM and BMD were assessed after 20 wk, and 4 wk later, rats were killed for levator ani muscle and prostate weights. Compared with ORX rats, 3beta,19-NA-treated rats had dose-dependent higher levator ani muscle weights, LBM, and BMD, which were similar to intact and DHT-treated rats at the highest 3beta,19-NA dose. In contrast, prostate weights in all 3beta,19-NA-treated groups were similar to ORX rats and lower than intact and DHT- and 19-nortestosterone-treated rats even at the highest 3beta,19-NA dose. In summary, 3beta,19-NA increases muscle and bone mass without significant stimulation of prostate growth, suggesting it may have some properties of a steroidal selective androgen receptor modulator. Anabolic steroids such as 3beta,19-NA should be studied further to determine their mechanisms of tissue selectivity and effects in men.
Oral andro-related prohormone supplementation: do the potential risks outweigh the benefits?[Pubmed:12671199]
Can J Appl Physiol. 2003 Feb;28(1):102-16.
Androstenedione, 4-Androstenediol, 5-androstenediol, 19-norandrostenediol and 19-norandrostenedione are commonly referred to as "Andro" prohormones. Over the last few years, supplementation using these prohormones has been aggressively marketed to the general public. Supplement manufacturers often claim that Andro use improves serum testosterone concentrations, increases muscular strength and muscle mass, helps to reduce body fatness, enhances mood, and improves sexual performance. However, to date, most studies contradict these claims. In contrast, several studies using oral Andro related prohormones show that Andro use can abnormally elevate estrogen related hormones as well as alterations in hormonal markers (i.e., abnormal elevations in serum estrogen) thought to increase a person's risk for developing prostate or pancreatic cancers. In addition, most studies also indicate that significant declines in high-density lipoproteins occur leading to an increased cardiovascular disease risk. Thus, to date, the current research base suggests that Andro prohormone use does not support manufacturer claims. But it does suggest there should be strong concerns regarding long-term oral Andro prohormone use, especially regarding its effects on blood lipids and estrogen hormone profiles.
[Urinary nandrolone metabolites in antidoping control].[Pubmed:11787429]
Ann Pharm Fr. 2001 Sep;59(5):345-9.
The French National Laboratory of the International Olympic Committee (IOC) has detected norandrosterone (NA) and noretiocholanolone (NE) in urine samples from several sportsmen. These two substances are known to be urinary metabolites after nandrolone intake. In such cases, the NA level is always higher than the Ne level. However, in the urine samples of sportsmen tested positive, the NE concentrations were systematically higher than the NA levels. We therefore searched for other steroid precursors (commercially available capsules or tablets of dehydroepiandrosterone, 4-Androstenediol, 5-androstenediol, 4-androstenedione, 19-norandrostenediol and 19-norandrostenedione, also illegally used in France) which could lead to an excretion of NA and NE and to an inverted ratio of these metabolites.